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ABSTRACT Using live microbes as therapeutic candidates is a strategy that has
gained traction across multiple therapeutic areas. In the skin, commensal microor-
ganisms play a crucial role in maintaining skin barrier function, homeostasis, and cu-
taneous immunity. Alterations of the homeostatic skin microbiome are associated
with a number of skin diseases. Here, we present the design of an engineered com-
mensal organism, Staphylococcus epidermidis, for use as a live biotherapeutic product
(LBP) candidate for skin diseases. The development of novel bacterial strains whose
growth can be controlled without the use of antibiotics or genetic elements confer-
ring antibiotic resistance enables modulation of therapeutic exposure and improves
safety. We therefore constructed an auxotrophic strain of S. epidermidis that requires
exogenously supplied D-alanine. The S. epidermidis NRRL B-4268 Δalr1 Δalr2 Δdat
strain (SEΔΔΔ) contains deletions of three biosynthetic genes: two alanine racemase
genes, alr1 and alr2 (SE1674 and SE1079), and the D-alanine aminotransferase gene,
dat (SE1423). These three deletions restricted growth in D-alanine-deficient medium,
pooled human blood, and skin. In the presence of D-alanine, SEΔΔΔ colonized and in-
creased expression of human -defensin 2 in cultured human skin models in vitro.
SEΔΔΔ showed a low propensity to revert to D-alanine prototrophy and did not form
biofilms on plastic in vitro. These studies support the potential safety and utility of
SEΔΔΔ as a live biotherapeutic strain whose growth can be controlled by D-alanine.
IMPORTANCE The skin microbiome is rich in opportunities for novel therapeutics
for skin diseases, and synthetic biology offers the advantage of providing novel
functionality or therapeutic benefit to live biotherapeutic products. The develop-
ment of novel bacterial strains whose growth can be controlled without the use of
antibiotics or genetic elements conferring antibiotic resistance enables modulation
of therapeutic exposure and improves safety. This study presents the design and in
vitro evidence of a skin commensal whose growth can be controlled through
D-alanine. The basis of this strain will support future clinical studies of this strain in
humans.
KEYWORDS microbiome, skin, engineering, genetics, therapeutics, live
biotherapeutic products, dermatology, synthetic biology
Commensal microorganisms play a crucial role in maintaining human health acrossa number of organ systems, particularly in the skin (1–7). Diverse communities of
microorganisms populate the skin, and a square centimeter can contain up to a billion
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microorganisms (8). These diverse communities of bacteria, fungi, mites, and viruses
can provide protection against disease and form dynamic, yet distinct, niches on the
skin (9). Increasing evidence has associated altered microbial communities or dysbiosis
in the skin with cutaneous diseases (8, 10), especially atopic dermatitis (11–13). New
strategies have emerged using microbes as therapy for treating a range of diseases (14).
While this approach has gained particular attention in developing biotherapeutics for
gastrointestinal diseases (15, 16), few studies have reported on using live microbes to
treat skin diseases.
Staphylococcus epidermidis, recently dubbed the “microbial guardian of skin health”
(17), is a strong candidate for use as a live biotherapeutic product (LBP) for skin
conditions. S. epidermidis is a Gram-positive bacterium that is ubiquitous in the human
skin and mucosal flora. As one of the earliest colonizers of the skin after birth, S.
epidermidis plays an important role in cutaneous immunity and maintaining microbial
community homeostasis (18, 19). In the clinical setting, S. epidermidis has demonstrated
activity as a potential therapeutic (20–22). In Japan, in a double-blind, randomized
clinical trial, topical application of autologous S. epidermidis in healthy volunteers
increased lipid content of the skin, suppressed water evaporation, and improved skin
moisture retention without signs of erythema (20). Other investigators have shown that
S. epidermidis is capable of producing antimicrobial peptides (AMPs) that selectively
target Staphylococcus aureus (23, 24). S. epidermidis has also shown other potent,
therapeutic effects in preclinical settings. For example, a recent report described
antineoplastic properties of certain strains of S. epidermidis (21). Naik et al. found that
S. epidermidis (from the A20 clade) applied to the skin of germfree mice resulted in the
development of protection against specific cutaneous pathogens (25). Other studies
have shown that S. epidermidis may enhance innate skin immunity and limit pathogen
invasion (19). In addition, S. epidermidis produces lipoteichoic acid, which can suppress
Toll-like receptor 3 (TLR3)-mediated inflammation and protect mice from S. aureus
infection (26, 27). Moreover, recent evidence suggests that topical S. epidermidis
application is able to induce a nonclassical major histocompatibility complex class I
(MHC-I)-restricted immune response to not only promote protection against pathogens
but also accelerate wound repair in skin (18). The introduction of S. epidermidis could
also aid in reestablishing skin homeostasis by targeting pathogen-driven dysbiosis.
Translational use of S. epidermidis in humans ideally requires controlling the viability
and growth of the microbe, particularly in the manipulation, formulation, and life span
of the therapeutic strain. While genetic manipulation of the strain using classical
antibiotic selection markers could achieve this control, this method is discouraged by
the Food and Drug Administration (FDA) for use in the final design of an LBP (14). Here,
we propose an elegant solution for controlling an S. epidermidis strain for therapeutic
use by introducing D-alanine auxotrophy. D-Alanine is required for the synthesis of
peptidoglycans, which are essential components of the bacterial cell wall. D-Alanine is
not normally present at significant levels in human tissue; so bacteria must produce it
biosynthetically, or it must be supplied exogenously. In bacteria, biosynthesis is ac-
complished through the action of alanine racemase, which interconverts L-alanine and
D-alanine, and by D-alanine aminotransferase, which interconverts D-glutamic acid and
D-alanine. The metabolic pathway requirement for D-alanine auxotrophy varies in
different genetic backgrounds. It was reported that the presence of glutamate race-
mase (interconverting D-glutamate and L-glutamate) with D-alanine aminotransferase
(interconverting D-alanine and D-glutamate) provides a bypass for alanine racemase in
S. aureus and Listeria monocytogenes (28, 29). In the present study, we found that, in S.
epidermidis, it was necessary to knock out the D-alanine aminotransferase gene (SE1423)
in addition to the two alanine racemase enzymes, alr1 (SE1674) and alr2 (SE1079), to
fully confer the auxotrophic phenotype.
Here, we describe a strategy for generating a D-alanine-auxotrophic strain of S.
epidermidis. This approach permitted tunable and precise control of growth of the
organism. We further characterized its growth in culture and human blood and its
colonization and activity in cultured skin models in vitro.
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RESULTS
Knocking out both alanine racemase genes, alr1 and alr2, in S. epidermidis NRRL
B-4268 (Δalr1 Δalr2) did not produce an auxotrophic phenotype for D-alanine, in
contrast to similar genetic knockouts in other bacteria such as Bacillus subtilis (30). This
suggested that there was another metabolic pathway that could result in the produc-
tion of D-alanine. The dat gene, encoding D-alanine aminotransferase, was identified as
a candidate gene to knock out in order to eliminate potential interconversion of
D-glutamate to D-alanine (Fig. 1A). The resulting triple-knockout strain, S. epidermidis
Δalr1 Δalr2 Δdat (SEΔΔΔ), was successfully generated and displayed the desired
D-alanine auxotrophy. All candidate clones (numbers 7, 12, and 18) showed some
growth in an initial screen on tryptic soy agar (TSA) medium supplemented with
40 g/ml D-alanine and failed to grow in the absence of supplementation (Fig. 1B). All
three chromosomal deletions were similarly confirmed by PCR in each of the three
candidate clones, numbers 7, 12, and 18, as illustrated in the example for SE1423 shown
in Fig. 1C and D.
During strain construction, it was also noted that a Δdat mutation alone in the
absence of the Δalr1 Δalr2mutations had no effect on the growth of the mutated strain
in the absence of D-alanine (data not shown). Further, attempts to engineer a mutation
in the glutamate racemase gene, murI, were unsuccessful, possibly due to the multi-
functional nature of this protein, which has been observed in other bacteria (data not
shown) (31, 32). The entire genomes of the S. epidermidis Δalr1 Δalr2 Δdat mutant and
parental strain NRRL B-4268, as well as the genome of the ATCC 12228 strain, were
FIG 1 Strategy for D-alanine auxotrophy. (A) Alanine metabolism in staphylococcal species and the strategy for
constructing a S. epidermidis D-alanine auxotroph. (B) The construction of S. epidermidis Δalr1 Δalr2 Δdat is described in
Materials and Methods. Twenty-five candidate clones were patched onto two different plates, and the plates were
incubated at 30°C overnight. Left, TSA plate; right, TSA plus anhydrotetracycline (2 g/ml) and D-alanine (40 g/ml). Three
clones (7, 12, and 18, highlighted in yellow circles) could only grow on TSA supplemented with D-alanine. (C and D)
Example of PCR confirmation of gene knockout for S. epidermidis 1423 in SEΔΔΔ candidates. The DNA from cells patched
onto a plate containing TSA plus anhydrotetracycline (2 g/ml) and D-alanine (40 g/ml) was used as the template in PCRs.
Gel lanes are shown for the indicated knockout clones (7, 12, and 18), wild-type (WT) S. epidermidis, and SE1423KO plasmid
DNA (Vector; as a control). For the experiment shown in panel C, PCR was performed using primers 1423-5F and 1423-3R
to distinguish the wild-type SE1423 locus (PCR product of 2.3 kb) and the SE1423 knockout (PCR product of 1.5 kb). For
the experiment shown in panel D, PCR was performed using primers 1423-F and 1423-R to detect a PCR product of 0.7 kb,
specific for the wild-type SE1423 locus. As expected, the PCR products were not generated from the SE1423 knockout
plasmid and putative SE1423 knockout S. epidermidis clones. Results confirmed successful SE1423 deletion in clones 7, 12,
and 18, and similar PCR analysis was done to confirm deletions of SE1674 and SE1079.
Controlling the Growth of S. epidermidis
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sequenced using a long-read methodology (PacBio, Menlo Park, CA) and assembled; no
significant differences from the published sequences were observed except intended
deletions in the alr1, alr2, and dat genes in the mutant (data not shown) (ATCC 12228;
GenBank accession numbers AE015929 and CP043845). Further, complementation of
the D-alanine auxotrophy by a plasmid containing the B. subtilis alanine racemase gene
(alrA) confirmed that the auxotrophy was due to disruption of the D-alanine biosyn-
thetic pathway, as expected from the three engineered deletions (data not shown).
In order to determine the frequency of reversion from D-alanine auxotrophy to
prototrophy of SEΔΔΔ, concentrated cell suspensions were plated on Vegitone agar
without D-alanine supplementation and compared to cells on plates with D-alanine. The
result indicates that no phenotypic revertants developed in the absence of D-alanine,
with an estimated frequency of reversion of less than 4.8 1011 revertants/CFU
plated. In the same strain, the frequency of spontaneous rifampin resistance emergence
was 6 108 mutants/CFU plated, demonstrating that the conditions of this experi-
ment were able to select for mutations in strain SEΔΔΔ (see Fig. S1 in the supplemental
material).
Characteristics of SE growth in broth cultures. The kinetics of SEΔΔΔ growth
in Vegitone broth were evaluated at 37°C with increasing concentrations of D-alanine
(Fig. 2A). After 7 h, growth approached stationary phase, independently of the
D-alanine concentration, such that generation times could be estimated using a stan-
dard logistic equation. From this, the estimated generation time was31 to 45 min. No
growth of the SEΔΔΔ strain was measured in the absence of D-alanine after 7 h, in
agreement with the auxotrophic nature of the bacteria. There was no correlation
between generation time and D-alanine concentration. The growth of SEΔΔΔ was very
FIG 2 Characterization of SEΔΔΔ growth in vitro. (A) Graph showing the effect of D-alanine concentration
(from 0 to 20 g/ml) on the change in the OD at 600 nm over the time of incubation at 37°C for SEΔΔΔ. Each
data point is the mean  standard deviation of three independent replicates. Dashed lines are the results
from the logistic fit. As described in Materials and Methods, cultures were inoculated to a starting OD600 of
0.1, which corresponded to approximately 1 107 CFU/ml. (B) EC50 curve of D-alanine concentration on the
area under the concentration-time curve (AUC). (C) Graph showing the effect of temperature on the growth
kinetics of SEΔΔΔ. Growth curves were generated at room temperature and at 37°C using a D-alanine
concentration of 100 g/ml. One culture was placed into the incubator shaker (37°C; 250 rpm), and the
second culture was placed at room temperature in a shaker (250 rpm). (D) Graph showing the effect of pH
on the growth kinetics of SEΔΔΔ. Growth curves, at 37°C, were generated from Vegitone medium that had
been adjusted to pH 5 or 6 or the standard pH 7.0. D-Alanine was then added to obtain a final concentration
of 100 g/ml.
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sensitive to the D-alanine concentration, as indicated by a steep Hill slope (11) of the
concentration-growth curve (data not shown). The D-alanine concentration needed for
the half-maximal response (50% effective concentration [EC50]) was 54 g/ml (0.005%)
(Fig. 2B). As there was no difference in the growth curves between conditions using 80
and 200 g/ml of D-alanine, the standard concentration of D-alanine for routine growth
of the auxotroph was set at 100 g/ml. The growth of the auxotroph SEΔΔΔ strain in the
presence of 100 g/ml of D-alanine was similar to that of the wild-type parent, NRRL
B-4268, at 37°C, further supporting that the only phenotype conferred by the triple
deletion is D-alanine auxotrophy (Fig. S2).
At room temperature, SEΔΔΔ showed little to no growth, as monitored by the optical
density at 600 nm (OD600) (Fig. 2C) though the culture density increased by 2 log10
CFU over a 30-h time period (data not shown). The comparator culture grown at 37°C
had a log10 CFU increase of 6 (data not shown) and reached stationary phase within
4 h from the end of lag phase (Fig. 2C).
Skin surface pH ranges from4 to 6, compared to below the skin surface, which has
a pH around 7 (34); therefore growth at lower pH in broth cultures was evaluated. SEΔΔΔ
cultures grown at 37°C in standard Vegitone broth pH (7.0) and in broth adjusted to pH
6.0 each increased by 6 log10 CFU (data not shown) and reached stationary phase
within 4 h from the end of the lag phase, showing generation times of 45.5 min and
35.5 min, respectively (Fig. 2D). The growth rate at pH 5.0 was somewhat lower
(generation time of 65 min) and showed a more pronounced lag phase, yet cultures
grew to about the same final cell densities as with medium at pH 6 and 7 (Fig. 2D).
SEΔΔΔ showed no growth at pH 4 (data not shown).
Characteristics of SE safety.We looked at three characteristics of SEΔΔΔ related
to safety: (i) the ability of SEΔΔΔ to grow in human blood, (ii) its antibiotic resistance/
susceptibility, and (iii) its potential to grow a biofilm. To test the ability of SEΔΔΔ to grow
should it unintentionally enter the bloodstream, growth was assessed for 24 h in
defibrinated human blood. SEΔΔΔ inoculated in human blood without D-alanine showed
no growth after an overnight incubation with inocula of less than 1.4 108 CFU/ml, but
human blood supplemented with D-alanine was capable of supporting growth at all
levels of inocula tested (except the lowest inoculum concentration of 1 100) (Ta-
ble S3). The CFU counts of blood cultures inoculated with 1.4 108 CFU/ml remained
constant, with no further growth or loss of viability under the conditions of this assay.
The antibiotic susceptibility profiles of NRRL B-4268 and SEΔΔΔ were determined
using CLSI methodology. Table 1 shows that the SEΔΔΔ strain has antibiotic suscepti-
bility similar to that of the parent wild-type S. epidermidis NRRL B-4268, and results were
consistent with a prior literature report (35).
Finally, we looked at the ability of SEΔΔΔ to form biofilm. This experiment was
performed on polystyrene plastic, and growth was evaluated in a standard crystal violet
assay in a 96-well format. Cultures were grown in tryptic soy broth (TSB)–0.5%
D-glucose, with and without D-alanine, and biofilm formation was detected and quan-
tified using crystal violet. The data in Fig. 3 show that the crystal violet staining for
SEΔΔΔ, with or without D-alanine present, was indistinguishable from that of the blank
and TSB controls, indicating that no biofilms formed on the plastic under the conditions
of this assay. Wells containing the positive-control strain, SE1457, showed strong crystal
violet staining, consistent with this strain’s known ica-positive genotype and biofilm-
forming phenotype.
SE colonization of a human skin model in vitro. To determine if D-alanine
supplementation is necessary for SEΔΔΔ colonization and survival on reconstructed
human epidermis (RHE), 105 CFU of SEΔΔΔ was inoculated onto the RHE surface either
with or without D-alanine supplementation. No colonization occurred without D-alanine
present, indicating that D-alanine must be supplied for growth on skin (Fig. 4). Further-
more, these data show that SEΔΔΔ colonized the RHE within 4 h and persisted for up to
72 h following a single application with D-alanine supplementation. Interestingly, as
early as 4 h postinoculation, in the absence of D-alanine, no bacteria were recovered
Controlling the Growth of S. epidermidis
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from the RHE when homogenates were plated on SaSelect plates supplemented with
D-alanine.
SEΔΔΔ was also evaluated for its ability to trigger host-commensal communication.
SEΔΔΔ was seeded on RHE inserts, and mRNA levels for specific host-commensal signals
were measured by quantitative PCR (qPCR). In Fig. 5, data show a trend in the change
in expression levels of two epithelial AMPs, S100 calcium-binding protein A7 (S100A7)
and human -defensin 2 (hD-2). In this sample (n 3), the average expression levels
TABLE 1 Antibiotic susceptibility of SEΔΔΔ versus the parent S. epidermidis strain
Antibiotic
MIC (g/ml)
SusceptibilityaSE NRRL B-4268
Ampicillin 4 4 NA
Bacitracin 16 16 NA
Cefalexin 2 2 NA
Ceftaroline 0.12 0.12 S
Chloramphenicol 2 2 S
Clindamycin 0.06 0.06 S
Daptomycin 0.5 0.5 S
Doxycycline 4 4 S
Erythromycin 0.12 0.12 S
Fosfomycin 4 4 NA
Fusidic acid 0.03 0.03 NA
Gentamicin 0.06 0.06 S
Levofloxacin 0.12 0.12 S
Linezolid 0.5 0.5 S
Mupirocin 0.12 0.12 NA
Oritavancin 0.03 0.06 S
Oxacillin 0.12 0.12 S
Quinupristin/dalfopristin 0.12 0.12 S
Rifampin 0.002 0.002 S
Tetracycline 32 32 R
Tigecycline 0.25 0.12 - 0.25 S
Trimethoprim/sulfamethoxazole 0.5/9.5 0.5/9.5 S
Vancomycin 1 1 S
aAccording to CLSI breakpoints: S, sensitive; R, resistant. NA, not available.
FIG 3 The production of biofilm from S. epidermidis in vitro. The bottom panel shows the accumulation
of biofilm on plastic wells within 24 h at 37°C, visualized by crystal violet staining. Biofilm formation was
further quantified by dissolving the crystal violet in acetic acid and reading absorbance at 570 nm. S.
epidermidis strain 1457 was the positive control, and the blank and TSB medium-only wells served as
negative controls for background staining. All data shown are means  standard deviations of 16
replicate microtiter wells.
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of both AMPs were heightened in the presence of SEΔΔΔ. No deleterious effects of the
SEΔΔΔ colonization on the structure of the RHE were observed histologically.
DISCUSSION
A strategy is presented for the construction of an S. epidermidis strain, SEΔΔΔ, with
a non-antibiotic-associated conditional growth phenotype. SEΔΔΔ, exhibits key features
that support its potential as a skin LBP: its growth is tunable with D-alanine, its D-alanine
auxotrophy has a low propensity to phenotypically revert, it colonizes human skin
equivalents, it does not grow in pooled human blood, it does not form biofilms on
plastic, and it increases expression of an important host AMP, hD-2. Our strategy
involved deleting the ability to synthesize D-alanine, which is required for the synthesis
of bacterial cell peptidoglycan. Here, we show that, as expected, disruption of pepti-
doglycan through D-alanine starvation is bactericidal in culture and on skin in vitro. In
contrast to reports for B. subtilis, in order to develop D-alanine auxotrophy in S.
FIG 4 SEΔΔΔ growth in RHE. RHE inserts were colonized with SEΔΔΔ at 37°C in 5% CO2. D-Alanine at
100 g/ml ( D-Ala) was added to the medium feeding the RHE insert, as indicated. Colonized models
were harvested at each time point by uniform skin punches. Skin punch samples were rinsed in DPBS to
remove nonadherent cells, vortexed, and assayed for cell density by serial dilution and plating on
SaSelect plates supplemented with 100 g/ml of D-alanine. Each condition was tested in triplicate.
FIG 5 Expression of human AMPs following SEΔΔΔ treatment of RHE. (A and B) Plots of the changes in
mRNA levels for two epithelial AMPs (S100A7 and hD-2). hD-2 was elevated in the presence of SEΔΔΔ.
(C) Hematoxylin and eosin staining of transverse sections of RHE inserts with or without treatment with
SEΔΔΔ. The vehicle control was PBS containing 100 g/ml D-alanine. ns, not significant. *, P 	 0.05.
Horizontal lines indicate medians.
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epidermidis, not only the two alanine racemase genes (alr1 and alr2) but also the
D-alanine aminotransferase gene, dat, had to be knocked out. Evidently, the combina-
tion of glutamate racemase and D-alanine aminotransferase provides a viable bypass to
alanine racemase, as reported in MRSA132 (28) and Listeria monocytogenes (29). Other
investigators have reported on other auxotrophy strategies for attenuating growth in
S. aureus, including proline (36), menadione (37), and NK41 (38).
Several findings from these studies support the idea that attenuation by D-alanine
auxotrophy may promote the safety of SEΔΔΔ for use as a skin LBP. The very low
spontaneous reversion rate of D-alanine auxotrophy suggests that very large doses of
SEΔΔΔ may be applied to skin without selecting for a prototrophic revertant. Further,
results also support that the D-alanine auxotrophy of SEΔΔΔ may mitigate the risk of
bacterial dissemination into the bloodstream. Biofilm-forming S. epidermidis is often
associated with opportunistic nosocomial infections due to the ability to colonize
biomaterials of indwelling medical devices (39, 40). Therefore, biofilm formation is an
undesirable property of an LBP. No biofilm formation was seen with SEΔΔΔ, with and
without D-alanine, suggesting that this strain may have a lower propensity to form
biofilm in a clinical setting. Another important observation is that the inability to form
biofilm in vitro did not affect the ability of SEΔΔΔ to robustly colonize and grow on RHE.
S. epidermidis belongs to the group of coagulase-negative staphylococci (CoNS),
which is distinguished from coagulase-positive staphylococci such as S. aureus by
lacking the enzyme coagulase. A large arsenal of tools is available to S. epidermidis to
control the colonization of other pathogenic microorganisms, including proteases that
degrade proteins in S. aureus biofilm, stimulation of AMP secretion from keratinocytes,
or secretion of lantibiotics targeting S. aureus (41–47). In addition, S. epidermidis
produces lipoteichoic acid, which can suppress TLR3-mediated inflammation and pro-
tect mice from S. aureus infection (48). Specific novel lantibiotics secreted by S.
epidermidis and Staphylococcus hominis were recently shown to control S. aureus
infection by synergizing with the human keratinocyte-secreting cathelicidin-related
AMP LL-37 (49). This is a further demonstration of the important and beneficial interplay
between commensals and the host. Interestingly, these lantibiotic-secreting strains
were significantly underrepresented in the microbiome of atopic dermatitis patients,
and exogenous application of these lantibiotic-secreting commensals resulted in a
reduction in S. aureus infection in a small group of atopic dermatitis patients (49).
Introduction of D-alanine auxotrophy into other S. epidermidis strain backgrounds may
be a way of broadly controlling isolates selected for their novel therapeutic properties.
Skin innate immunity is the first line of defense after the physical skin barrier.
Keratinocytes are the main skin cell population involved (50–52); they express a variety
of TLRs, which are primary sensors of innate immunity (53, 54). The innate immune
system can recognize pathogens and trigger the host response to eliminate them via
the release of cytokines (e.g., interleukin-1 [IL-1] and IL-1) and AMPs (51, 55–57).
AMPs are secreted by keratinocytes, sebocytes, T cells, and mast cells and can directly
attack pathogens (e.g., bacteria, enveloped viruses, and fungi) (58–61). AMPs can be
grouped into five separate classes: defensins, dermcidin, cathelicidins, S100 proteins,
and ribonucleases (61–63). Some are constitutively expressed while others can be
induced following a skin insult. AMPs are highly cationic and thus interact with
negatively charged membrane components (e.g., lipopolysaccharide [LPS], peptidogly-
cans, outer membrane protein I [OprI]) of skin pathogens, essentially forming holes in
the cell membrane (58). AMPs have also been shown to exert immunomodulatory
effects, interacting directly with receptors on immune cells to promote chemotaxis,
differentiation, and cytokine production (39). The most abundant AMPs in human skin
are human defensins, the cathelicidin LL-37, and RNase 7. Several studies have shown
that commensal organisms such as S. epidermidis can directly induce expression of
hD-2 (hDEFB4A gene) while presenting a relative tolerance to it, enabling such
organisms to survive on the skin surface and to modulate defensin expression when the
stratum corneum barrier is disrupted (64). Therefore, commensal bacteria such as S.
epidermidis are able to amplify the innate immune response of human keratinocytes to
Dodds et al.
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pathogens by induction of AMP expression (62). Our SEΔΔΔ auxotroph promoted the
expression hD-2, a key AMP in the skin that has been shown to inhibit S. aureus, thus
demonstrating its ability to favorably modulate host innate immunity (65).
This study had several limitations, including the restriction of using reconstructed
human epidermis instead of in vivo studies. However, given evidence that S. epidermidis
does not natively colonize mice and the poor translation of microbiome studies in mice
to humans (66), in vivo studies themselves carry limitations. Three-dimensional in vitro
skin models like the RHE we developed in this study have been established to study
human microbiota on the skin as an alternative to in vivo studies (67). Future clinical
testing of SEΔΔΔ in humans will provide key information in vivo such as growth on live
skin, competition with other microbes, and safety.
In this study, we describe the engineering of a live skin commensal, S. epidermidis,
and characterize its favorable properties which support its potential use as an LBP for
skin diseases. Properties conferred by the D-alanine auxotrophy and the strain back-
ground itself support the potential of SEΔΔΔ to serve either as an LBP itself or as a
recombinant host for expressing novel skin therapeutics. Future studies will evaluate
the effect of this LBP candidate on human skin in the clinical setting.
MATERIALS AND METHODS
Generation and confirmation of auxotrophy. The commensal, nonpathogenic strain S. epidermidis,
NRRL B-4268 was obtained from the USDA (Agricultural Research Service, NRRL culture collection, Peoria,
IL, USA). This strain is also known as ATCC 12228 (American Type Culture Collection, Manassas, VA, USA)
and PCI 1200 (U.S. FDA). This strain was selected for its low virulence potential because it lacks the ica
operon implicated in S. epidermidis-associated catheter bloodstream infections (68).
The reference genome has been published as the ATCC 12228 genome (35, 69). The genome encodes
two annotated alanine racemase genes, SE1674 (alr1) and SE1079 (alr2); both genes were targeted for
deletion. The strategy for conferring D-alanine auxotrophy to NRRL B-4268 is presented in Fig. 1A Briefly,
chromosomal DNA from S. epidermidis NRRL B-4268 was isolated and used as a template for PCR. The 5=
flanking region (1.0 kb) of SE1674 was amplified using forward primer 1674-5F (SalI) and reverse primer
1674-5R. Similarly, the 3= flanking region (1.0 kb) of SE1674 was amplified using forward primer 1674-3F
and reverse primer 1674-3R (EcoRI). Overlapping PCR was performed using a mixture of the 5= PCR and
3= PCR products as templates, and primers 1674-5F (SalI) and 1674-3R (EcoRI) to generate a PCR product,
termed 5=-1674-3= (2.0 kb).
The overlapping PCR product 5=-1674-3= was digested with SalI and EcoRI, cloned into the
temperature-sensitive plasmid pJB38 at the EcoRI-SalI sites (70), and transformed into TOP10 Escherichia
coli (Life Technologies, Inc., Carlsbad, CA, USA) using ampicillin selection (100 g/ml) to develop
knockout (KO) plasmid pJB-1674KO that contains a chloramphenicol (Cm) resistance selection marker.
Plasmid pJB-1674KO was purified and transformed into E. coli GM2163 (a dam dcm mutant) using
ampicillin selection (100 g/ml) and then purified and transformed into NRRL B-4268 by electroporation.
Transformants were grown at the permissive temperature (30°C) on tryptic soy agar plates (TSA)
containing 10 g/ml Cm. (see Tables S1 and S2 in the supplemental material for more information on the
strains, plasmids, and primers used.)
For each of the gene knockouts created in this study, the presence of each pJB38 KO plasmid in initial
S. epidermidis transformants was confirmed by PCR amplification of the flanking region of each gene.
Colonies of confirmed pJB38 KO plasmid transformants were restreaked onto fresh TSA with Cm
(10 g/ml) and D-alanine (40 g/ml), and plates were incubated at 43°C for 24 h to select for plasmid
integration into the chromosome via single-crossover homologous recombination. Isolated colonies
were streaked again for purification at 43°C and then inoculated into 50 ml of tryptic soy broth (TSB) plus
D-alanine (40 g/ml), without Cm, in a 250-ml baffled shake flask and grown at 30°C for 24 h to permit
the excision of plasmid sequences from the chromosome by homologous recombination. The culture
was passaged six times by transferring an aliquot of 0.5 ml to a flask containing 50 ml of fresh medium
and growing the culture at 30°C for 24 h. The final culture was plated on TSA with 2 g/ml anhydro-
tetracycline (to induce plasmid counterselection) and D-alanine (40 g/ml). After 2 days of incubation at
30°C, approximately 100 to 200 colonies were formed on plates inoculated with 100 l of culture at a
105 dilution. Following integration of the KO plasmid and removal of the plasmid backbone containing
the antibiotic selection marker, an SE1674 knockout strain (S. epidermidis Δalr1) was isolated and
confirmed by PCR amplification using primers flanking the gene. Using the same gene knockout method
described above, we proceeded to knock out SE1079 in this strain, leading to successful generation of
double-knockout strains (S. epidermidis Δalr1 Δalr2). More information about the plasmids and PCR
primers used in this study can be found in Tables S1 and S2, respectively.
Measurement of effect of D-alanine levels on SE growth. The effect of D-alanine concentra-
tions ranging from 0 g/ml to 200 g/ml (0% to 0.02%) on the short-term growth curves of SEΔΔΔ was
investigated. Five milliliters of Vegitone medium (catalogue no. 41960; Sigma-Aldrich) containing 0.004%
(40 g/ml) D-alanine (99%; Acros Organics) was inoculated with an isolated SEΔΔΔ colony. Cultures were
incubated overnight at 37°C with shaking at 250 rpm on an orbital shaker.
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Growth rates were measured at 37°C for up to 7 h. Fifty milliliters of Vegitone containing the
prescribed amount of D-alanine was inoculated with 1 ml of the overnight culture to give a final optical
density (OD) at 600 nm of 0.1 relative units (RU). Flasks were incubated on an orbital shaker at 250 rpm.
Every 60 min, a sample was taken, and the OD600 was recorded. Growth curves were conducted for 7
h and were fitted using a standard logistic growth equation (71).
Measurement of effect of temperature and pH on SE growth. The effect of temperature and
medium pH on SEΔΔΔ growth were examined using 100 g/ml D-alanine in all groups. Growth curves
were measured at room temperature (25°C) and at 37°C for up to 40 h. Fifty milliliters of Vegitone
containing D-alanine was inoculated with 1.0 ml of the overnight culture. Growth curves were also
evaluated at three different pH values (pHs 4, 5, 6, and 7) at 37°C for 40 h.
Antibiotic susceptibility testing of S. epidermidis NRRL B-4268 and SE. Antibiotic suscepti-
bility testing was conducted at IHMA Europe Sàrl, Monthey, Switzerland, using Clinical and Laboratory
Standards Institute (CLSI) methodology, with the exception that 100 mg/liter D-alanine was added to
testing with SEΔΔΔ (72).
Determination of the frequency of spontaneous phenotypic reversion of auxotrophy of SE.
The D-alanine-deficient medium used to isolate revertants was Vegitone agar plates, prepared in 150-mm
petri dishes. Rifampin stocks were prepared in methanol at a final concentration of 4 g/ml. As
appropriate, Vegitone agar plates were prepared with either 100 g/ml of D-alanine or 8 ng/ml of
rifampin and 100 g/ml of D-alanine. Eight milliliters of the overnight culture was spun down at
10,000 rpm for 10 min. The pellets were resuspended in 1,200 l of Vegitone broth, and 150 l of the
suspension was spread onto 150-mm petri dishes. All plates were incubated at 37°C for 24 h. The
experiment was carried out in quadruplicate. The remaining inoculum suspension was serially diluted
1:10 in Vegitone broth and plated onto Vegitone agar plates supplemented with 100 g/ml D-alanine
and incubated at 37°C for 24 h to quantify CFU in the inoculum. The spontaneous resistance frequency
was determined by dividing the number of colonies grown in in the absence of D-alanine by the total
number of CFU plated.
Determination of growth of SE in blood. TSB supplemented with 100 g/ml of D-alanine was
inoculated with SEΔΔΔ and incubated overnight at 37°C. The overnight culture was further diluted in fresh
TSB plus D-alanine and allowed to grow until it reached mid-log phase, which corresponded to an
absorbance of0.7, as measured by the OD600. Virus-free, defibrinated pooled whole human blood from
three healthy donors was purchased from BioIVT (Westbury, NY). The SEΔΔΔ culture was concentrated to
1 109 CFU/ml. Serial 10-fold dilutions ranging from 1 109 to 1 101 were made in TSB with or
without D-alanine and then diluted again 10-fold into a volume of 100 l of blood in a 96-well microtiter
plate. All blood cultures were incubated in a tissue culture incubator at 37°C in 5% CO2 for 24 h. The
following day, cultures were serially diluted and plated on TSA with 100 g/ml of D-alanine, grown
overnight, and scored for the number of colonies. The experiment was carried out in duplicate. The
remaining inoculum suspension was serially diluted in TSB and plated onto TSA supplemented with 100
g/ml of D-alanine to quantify CFU in the inoculum. All plates were incubated at 37°C for 24 h.
Growth of SE on reconstructed human epidermis. Fully differentiated antibiotic-free recon-
structed human epidermis (RHE) culture inserts from Mattek (EpiDerm, Ashland, MA, USA) were used to
evaluate bacterial colonization. RHE models were reactivated by placing cell inserts into six-well plates
containing 1 ml of EpiDerm maintenance medium from Mattek. The inserts were then incubated for 18
h at 37°C in 5% CO2. Following incubation, the inserts were transferred to 12-well hanging culture inserts
with 5 ml of Epiderm maintenance medium in each well, and the tissues were incubated for an additional
30 min at 37°C in 5% CO2. When applicable, 100 g/ml of D-alanine was also added to the RHE medium.
SEΔΔΔ was inoculated into 25 ml of TSB containing 100 g/ml of D-alanine. The culture was grown at 37°C
overnight with shaking. After 18 h, fresh TSB supplemented with 100 g/ml of D-alanine was inoculated
with the overnight culture of SEΔΔΔ at a starting OD600 of 0.1. Cultures were grown at 37°C to log phase
(OD600 of 0.5 to 0.7), pelleted by centrifugation at 15,000 rpm for 2 min, and then resuspended in
Dulbecco’s phosphate-buffered saline (DPBS) to a final OD600 of 1.0. The bacterial pellet was suspended
in 1 ml of DPBS and pelleted at 15,000 rpm for 2 min. This process was repeated two more times to
ensure that residual D-alanine was removed from the bacterial suspension. The bacterial cells were next
diluted down to 0.01 OD600 in DPBS. For cells receiving D-alanine, 100 g/ml of D-alanine was added to
the bacterial suspension prior to RHE inoculation. To inoculate the RHE inserts, 10 l of the prepared
bacterial suspension was applied to the center of the dry surface-air interface of the RHE, ensuring that
the liquid droplet remained centered when possible. The RHE inserts were then incubated at 37°C in 5%
CO2 for 4 h, 24 h, 48 h, or 72 h. At each time point, bacterial colonization was assessed by taking a 4-mm
punch biopsy specimen from the center of the RHE. Biopsy specimens were washed by submerging the
tissue in 1 ml of DPBS to remove unadhered cells. In order to release the colonized bacterial cells from
the RHE, the biopsy specimens were transferred to 1 ml of DPBS, followed by vortexing for 2 min at full
speed. Colonization of SEΔΔΔ was quantified by dilution plating and counting CFU on SaSelect plates
supplemented with 100 g/ml D-alanine (Bio-Rad, Hercules, CA). All experiments were done in triplicate.
Biofilm formation assay with SE. The biofilm assay was adapted from Mack et al. and Neopane
et al. (73, 74). TSB was inoculated with S. epidermidis strain SEΔΔΔ and the biofilm-forming strain S.
epidermidis 1457 (75) and incubated overnight at 37°C. The culture was then diluted 1:200 in fresh
TSB–0.5% glucose, and 200 l was dispensed into a flat-bottom, 96-well tissue culture plate (Thermo
Fisher Scientific, Waltham, MA). The plate was incubated at 37°C for 24 h. After incubation, the microtiter
plate was washed twice with 1 DPBS to remove loosely attached bacterial and planktonic cells. The
biofilms were fixed by incubation in 200 l of 99% methanol for 10 min. The methanol was decanted, and
wells were allowed to air dry for 10 min. Once dry, wells were stained with 0.1% crystal violet for 5 min.
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Excess crystal violet was washed twice with deionized water. Wells were air dried, and then stained
biofilms were removed by dissolving them in 200 l of 30% glacial acetic acid. The amount of biofilm was
quantified by measuring absorbance of the plate at 570 nm.
Effect of SE on AMP production in cultured human skin. The effect of SEΔΔΔ on antimicrobial
peptide (AMP) production in cultured human skin was determined at StratiCELL (Les Isnes, Belgium)
using RHE inserts. RHE inserts were cultured in triplicates at the air-liquid interface for 14 days in
gentamicin-free culture medium containing D-alanine (100 g/ml) in 95% humidity at 37°C with 5% CO2
to fully differentiate the RHE. A single topical treatment with SEΔΔΔ (10 l at a cell density of 1 107
CFU/ml in phosphate-buffered saline [PBS] plus 100 g/ml D-alanine) was allowed to colonize for 48 h on
fully differentiated epidermis. Control samples were treated with 10 l of the vehicle solution (PBS plus
D-alanine 100 g/ml). During the treatment, the tissue culture medium feeding the RHE was also
supplemented with 100 g/ml D-alanine. RHE inserts were kept at the air-liquid interface in a humid
atmosphere at 37°C with 5% CO2.
Histological analysis of RHE. At the end of the treatment, three tissue samples per condition were
fixed in 4% formaldehyde, dehydrated, and paraffin embedded. Sections of 6 m of epidermis were
stained with eosin and hematoxylin. Slides were mounted with specific medium and examined with a
Leica DM2000 photomicroscope coupled to a digital camera (Zeiss).
Analysis of AMP expression in RHE. To quantify gene expression of human AMPs, total mRNA was
extracted using a Qiagen RNeasy kit (Hilden, Germany). Tissues were washed in PBS, removed from their
inserts, and immersed directly in the lysis buffer. Extraction of mRNA was performed according to the
supplier’s recommendations. The collected mRNA was stored at –80°C. Reverse transcription was
performed with a high-capacity mRNA-to-cDNA kit (Applied Biosystems, Foster City, CA) from 1 g of
total mRNA, according to the manufacturer’s instructions.
The target sequences of the genes of interest, S100 calcium-binding protein A7 (S100A7) and human
-defensin 2 (DEFB4A), were amplified by using TaqMan gene expression assays (Applied Biosystems,
Foster City, CA). TaqMan probes were grafted with a fluorophore (6-carboxyfluorescein [FAM]) at their 5=
ends and with a fluorescence quencher in the 3= ends. PCRs were performed with a QuantStudio 7
real-time PCR system (Applied Biosystems, Foster City, CA). In order to normalize the results, a
housekeeping gene (2-microglobulin [B2M]) was used. The thermal cycles were programmed with
first one denaturation step at 95°C for 20 s. The amplification protocol followed with 40 cycles (1s
at 95°C and 20 s at 60°C). Threshold cycle (CT) values were obtained for each gene. Data were
analyzed by using the relative quantification (RQ) application available on the Applied Biosystems
website (and designed to perform relative quantification of gene expression using the comparative
CT [ΔΔCT] method) (76, 77).
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